These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Feenstra J; de Herder WW; ten Have SM; van den Beld AW; Feelders RA; Janssen JA; van der Lely AJ Lancet; 2005 May 7-13; 365(9471):1644-6. PubMed ID: 15885297 [TBL] [Abstract][Full Text] [Related]
23. [Novel pharmacologic therapies in acromegaly]. Góth M; Hubina E; Kovács L; Szabolcs I Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860 [TBL] [Abstract][Full Text] [Related]
24. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. Drake WM; Parkinson C; Besser GM; Trainer PJ Trends Endocrinol Metab; 2001 Nov; 12(9):408-13. PubMed ID: 11595543 [TBL] [Abstract][Full Text] [Related]
25. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061 [TBL] [Abstract][Full Text] [Related]
27. [Growth hormone receptor antagonists: potential indications]. Muller AF; Janssen JA; de Herder WW; van der Lely AJ Ned Tijdschr Geneeskd; 2001 Jan; 145(2):69-73. PubMed ID: 11225259 [TBL] [Abstract][Full Text] [Related]
30. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly. Trainer PJ; Drake WM; Perry LA; Taylor NF; Besser GM; Monson JP J Clin Endocrinol Metab; 2001 Jul; 86(7):2989-92. PubMed ID: 11443156 [TBL] [Abstract][Full Text] [Related]
31. Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. Giustina A; Ambrosio MR; Beck Peccoz P; Bogazzi F; Cannavo' S; De Marinis L; De Menis E; Grottoli S; Pivonello R J Endocrinol Invest; 2014 Oct; 37(10):1017-30. PubMed ID: 25245336 [No Abstract] [Full Text] [Related]
32. New perspectives in the medical treatment of acromegaly. Colao A; Pivonello R; Auriemma RS; Galdiero M; Guerra E; Milone F; De Leo M; Lombardi G J Endocrinol Invest; 2005; 28(11 Suppl International):58-66. PubMed ID: 16625847 [TBL] [Abstract][Full Text] [Related]
33. Long-term effects of pegvisomant in patients with acromegaly. Hodish I; Barkan A Nat Clin Pract Endocrinol Metab; 2008 Jun; 4(6):324-32. PubMed ID: 18431372 [TBL] [Abstract][Full Text] [Related]
34. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562 [TBL] [Abstract][Full Text] [Related]
36. The future of growth hormone antagonists. van der Lely AJ Curr Opin Pharmacol; 2002 Dec; 2(6):730-3. PubMed ID: 12482738 [TBL] [Abstract][Full Text] [Related]
37. Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. Brian SR; Bidlingmaier M; Wajnrajch MP; Weinzimer SA; Inzucchi SE J Clin Endocrinol Metab; 2007 Sep; 92(9):3374-7. PubMed ID: 17595256 [TBL] [Abstract][Full Text] [Related]
38. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Biering H; Saller B; Bauditz J; Pirlich M; Rudolph B; Johne A; Buchfelder M; Mann K; Droste M; Schreiber I; Lochs H; Strasburger CJ; Eur J Endocrinol; 2006 Feb; 154(2):213-20. PubMed ID: 16452533 [TBL] [Abstract][Full Text] [Related]
39. GH receptor antagonist: mechanism of action and clinical utility. Surya SK; Barkan AL Rev Endocr Metab Disord; 2005 Jan; 6(1):5-13. PubMed ID: 15711909 [TBL] [Abstract][Full Text] [Related]